Literature DB >> 220361

Changes in the concentration of plasma lipoproteins and apoproteins following the administration of Triton WR 1339 to rats.

T Ishikawa, N Fidge.   

Abstract

Changes in whole plasma and lipoprotien apoprotein concentrations were determined after a single injection of Triton WR 1339 into rats. Concentrations of apoproteins A-I (an activator of lecithin:cholesterol acyl transferase), arginine-rich apoprotein (ARP), and B apoprotein were measured by electroimmunoassay. The content of C-II apoprotein (an activaor of lipoprotein lipase) was estimated by the ability of plasma and lipoprotein fractions to promote hydrolysis of triglyceride in the presence of cow's milk lipase and also by isoelectric focusing on polyacrylamide gels. Apoproteins C-II and A-I were rapidly removed from high density lipoprotein (HDL) after Triton treatment and were recovered in the d 1.21 g/ml infranate fraction. A-I was then totally cleared from the plasma within 10--20 hr after injection. Arginine-rich apoprotein was removed from HDL and also partially cleared from the plasma. The rise in very low density lipoprotein (vldl) apoprotein that followed the removal of apoproteins from HDL was mostly antributed to the B apoprotein, although corresponding smaller increases were observed in VLDL ARP and C apoproteins. The triglyceride:cholesterol, triglyceride:protein, and B:C apoprotein ratios of VLDL more closely resembled nascent rather than plasma VLDL 10 hr after Triton injection. These studies suggest that the detergent may achieve its hyperlipidemic effct by disrupting HDL and thus removing the A-I and C-II proteins from a normal activating environment compirsing VLDL, HDL, and the enzymes. The possible involvement of intact HDL in VLDL catabolism is discussed in relation to other recent reports which also suggest that abnormalities of the VLDL-LDL system may be due to the absence of normal HDL.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 220361

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Intracerebroventricular leptin regulates hepatic cholesterol metabolism.

Authors:  Sonya Vanpatten; George B Karkanias; Luciano Rossetti; David E Cohen
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

2.  Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys.

Authors:  I J Goldberg; W S Blaner; T M Vanni; M Moukides; R Ramakrishnan
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  The Long Term Kinetic of Plasma Lipids and Lipoproteins in Tyloxapol Injected Rats.

Authors:  Mehdi Rasouli; Hanieh Tahmouri; Mahboobeh Mosavi-Mehr
Journal:  J Clin Diagn Res       Date:  2016-06-01

4.  Increased plasma triglyceride secretion in EFA-deficient rats fed diets with or without saturated fat.

Authors:  M A Williams; J Tinoco; I Hincenbergs; B Thomas
Journal:  Lipids       Date:  1989-05       Impact factor: 1.880

5.  ApoB100 is required for increased VLDL-triglyceride secretion by microsomal triglyceride transfer protein in ob/ob mice.

Authors:  Zhouji Chen; Elizabeth P Newberry; Jin Y Norris; Yan Xie; Jianyang Luo; Susan M Kennedy; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2008-06-02       Impact factor: 5.922

6.  Hepatic uptake of phospholipid-depleted chylomicrons in vivo. Comparison with the uptake of chylomicron remnants.

Authors:  J Borensztajn; T J Kotlar
Journal:  Biochem J       Date:  1981-12-15       Impact factor: 3.857

7.  Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.

Authors:  Xinqiang Huang; Chaofeng Yang; Chengliu Jin; Yongde Luo; Fen Wang; Wallace L McKeehan
Journal:  Mol Carcinog       Date:  2009-06       Impact factor: 4.784

8.  Bioenhancing effects of naringin on atorvastatin.

Authors:  Venkatesh Sama; Balaraju Pagilla; Rajeswari Chiluka; Ravi Alvala; Ravi Kumar Pola; Ramesh Mullangi
Journal:  ADMET DMPK       Date:  2019-06-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.